December 2025
Discussing PsA: Uveitis risk and treatment sequencing outcomes in axSpa and PsA
Join Professor Laura Coates and Phillip Mease as they discuss the top publications in the world of PsA. This month, the conversation covered the ‘the effectiveness and safety of upadacitinib with secukinumab and adalimumab’ and ‘the efficacy of long-term treatment with risankizumab across the updated GRAPPA domains and key related conditions of PsA’
November 2025
Discussing RA: Real-world evaluation of JAKi efficacy, persistence, and cardiovascular safety in RA
Join Professor Iain McInnes for the latest episode of Discussing RA on The Immune-Mediated Inflammatory Disease Forum. In this episode, he will review two papers. The first paper, by Hernández-Hernández et al. looks at clinical and demographic factors associated with UPA treatment persistence and assesses how cardiovascular risk minimization measures have impacted UPA prescription patterns. The second paper by Nozaki et al. evaluates the clinical efficacy and continuation rates of JAK inhibitors and TNF inhibitors in RA patients with poor prognosis factors.
Author Interview: Professor Filip Rob, 2025
Join Professor Peter Nash from the Griffith University in Brisbane, and Professor Filip Rob, the Department of head of the Dermatovenereology at the Second Faculty of Medicine, Charles University, University Hospital Bulovka, Prague, Czech Republic, as they discuss his recent paper ‘Efficacy, safety, and drug survival during the first year of biologic therapy for psoriasis in elderly versus younger patients’.
Webinar Highlights: Advancing Patient Care Through an Interdisciplinary Approach to IMIDs: Part 2
Professor Iain McInnes and Drs Grace Wright and Melinda Gooderham discuss all the highlights from 'Advancing patient care through an interdisciplinary approach to IMIDs: Part 2'.
October 2025
Discussing axSpA: Adalimumab dosing and uveitis recurrence in patients with ankylosing spondylitis
Join Dr Sofia Ramiro and Professor Xenofon Baraliakos as they discuss the top publications in the world of axSpA. This month, the conversation covered the Association between adalimumab dosing interval and uveitis recurrence in patients with ankylosing spondylitis.
Discussing RA: Long-term management of elderly patients with RA treated with tocilizumab
Join Professor Iain McInnes for the latest episode of Discussing RA on The Immune-Mediated Inflammatory Disease Forum. In this episode, he will review a paper by B Fautrel, in which authors compare patient characteristics and long-term management with tocilizumab in RA patients over and under 75 years of age, and tolerance of RA treatments.